Abstract
The past decade has seen significant advances in the available treatments for asthma. These include longer-acting bronchodilating agents, high topical potency inhaled corticosteroids, and agents that interfere with leukotriene production or action. Table 3 summarizes the clinical effects of the newer therapeutic agents reviewed. Experimental therapies for the steroid-dependent patient have also been discussed. Although clinical trials to date have established many of these as effective in asthma, the results of ongoing, large, multicenter studies investigating the relative merits of these therapies, alone and in combination, will further clarify how to maximize the utility of these agents in the treatment of asthma.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Administration, Inhalation
-
Administration, Topical
-
Adrenergic beta-Agonists / administration & dosage
-
Adrenergic beta-Agonists / therapeutic use
-
Albuterol / administration & dosage
-
Albuterol / analogs & derivatives
-
Albuterol / therapeutic use
-
Androstadienes / administration & dosage
-
Androstadienes / therapeutic use
-
Anti-Asthmatic Agents / administration & dosage
-
Anti-Asthmatic Agents / therapeutic use*
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / therapeutic use
-
Asthma / drug therapy*
-
Bronchodilator Agents / administration & dosage
-
Bronchodilator Agents / therapeutic use
-
Clinical Trials as Topic
-
Drug Combinations
-
Fluticasone
-
Glucocorticoids
-
Humans
-
Leukotriene Antagonists / therapeutic use
-
Multicenter Studies as Topic
-
Salmeterol Xinafoate
Substances
-
Adrenergic beta-Agonists
-
Androstadienes
-
Anti-Asthmatic Agents
-
Anti-Inflammatory Agents
-
Bronchodilator Agents
-
Drug Combinations
-
Glucocorticoids
-
Leukotriene Antagonists
-
Salmeterol Xinafoate
-
Fluticasone
-
Albuterol